1. Scrip
  2. >>Therapy Areas

AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount

 
• By Mandy Jackson

Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.

Syringes stuck in a dartboard

Sun Pharmaceutical Industries Ltd. is preparing to launch tildrakizumab – which is now under US FDA review – into a market with multiple new agents and where Novartis AG has shown that it will go to great lengths to grow and protect Cosentyx (secukinumab), which has become its second-best-selling product.

Sun, Novartis and multiple other players in the increasingly competitive psoriasis market presented results for approved and pipeline therapies during the American Academy of Dermatology (AAD) meeting Feb. 16 to 19 in San Diego

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.